Application 201616
- Type
- ANDA
- Sponsor
- CIPLA LIMITED
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | HYDROCHLOROTHIAZIDE; IRBESARTAN | HYDROCHLOROTHIAZIDE; IRBESARTAN | TABLET; ORAL | 12.5MG; 150MG | No | No |
| 002 | HYDROCHLOROTHIAZIDE; IRBESARTAN | HYDROCHLOROTHIAZIDE; IRBESARTAN | TABLET; ORAL | 12.5MG; 300MG | No | No |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.